We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
Read MoreHide Full Article
For Immediate Release
Chicago, IL –February 13, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Disney (DIS - Free Report) , Eli Lilly (LLY - Free Report) , U.S. Bancorp (USB - Free Report) , Prudential (PRU - Free Report) and Alexion .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for Disney, Eli Lilly and U.S. Bancorp
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Disney, Eli Lilly and U.S. Bancorp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Disney’s shares have gained 5.1% over the past year, outperforming the Zacks Media Conglomerates industry’s gain of 2.6% during the same period. Disney’s first-quarter fiscal 2019 results benefited from strong performance of Media Networks and Parks, Experiences & Consumer Products segments.
An increase in affiliate revenues and higher program sales at Cable Networks’ and Broadcasting boosted Media revenues. Parks revenues benefited from increase in guest spending and average daily room rates at domestic parks. The Zacks analyst thinks Disney’s content slate will likely get a significant boost following the completion of Fox transaction.
Notably, the combined entity received 37 nominations at this year’s Golden Globes. However, higher programming costs at ESPN and heavy investments in streaming services continue to hurt profitability. Softness experienced in Chinese tourism negatively impacted Shanghai Disney Resort results.
Shares of Eli Lily have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year, +54.9% vs. +6.2%. Lilly missed Q4 earnings estimates while beating the same for sales. However, Lilly lowered its guidance for 2019.
The Zacks analyst thinks revenue growth in 2019 will likely be driven by higher demand for newer drugs including Trulicity, Jardiance, Taltz, Verzenio as well as new migraine drug, Emgality as some older drugs like Cialis face generic competition. In 2018, Lilly made significant pipeline progress with several positive late-stage data readouts, multiple approvals and regulatory submissions.
Lilly also added promising new pipeline assets through business development deals. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line.
U.S. Bancorp’s shares have outperformed the Zacks Major Banks industry over the past six months, losing -3.5% vs -10.5%. The company possesses an impressive earnings surprise history, beating expectations in all the trailing four quarters. Fourth-quarter 2018 results reflected higher revenues, aided by elevated fee income. However, reduced mortgage banking revenues and high expenses were on the downside.
The Zacks analyst thinks U.S. Bancorp's prospects will likely get support from its solid business model, core franchise, lower tax rate, rising interest rate and diverse revenue streams. Also, its organic growth remains solid and will likely benefit from the improving economic scenario.
U.S. Bancorp remains well poised to grow through acquisitions. However, escalating expenses due to its ongoing investments in technology and likely increase in legal expenses remain concerns.
Other noteworthy reports we are featuring today include Prudential and Alexion.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
For Immediate Release
Chicago, IL –February 13, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Disney (DIS - Free Report) , Eli Lilly (LLY - Free Report) , U.S. Bancorp (USB - Free Report) , Prudential (PRU - Free Report) and Alexion .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for Disney, Eli Lilly and U.S. Bancorp
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Disney, Eli Lilly and U.S. Bancorp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Disney’s shares have gained 5.1% over the past year, outperforming the Zacks Media Conglomerates industry’s gain of 2.6% during the same period. Disney’s first-quarter fiscal 2019 results benefited from strong performance of Media Networks and Parks, Experiences & Consumer Products segments.
An increase in affiliate revenues and higher program sales at Cable Networks’ and Broadcasting boosted Media revenues. Parks revenues benefited from increase in guest spending and average daily room rates at domestic parks. The Zacks analyst thinks Disney’s content slate will likely get a significant boost following the completion of Fox transaction.
Notably, the combined entity received 37 nominations at this year’s Golden Globes. However, higher programming costs at ESPN and heavy investments in streaming services continue to hurt profitability. Softness experienced in Chinese tourism negatively impacted Shanghai Disney Resort results.
(You can read the full research report on Disney here >>>).
Shares of Eli Lily have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year, +54.9% vs. +6.2%. Lilly missed Q4 earnings estimates while beating the same for sales. However, Lilly lowered its guidance for 2019.
The Zacks analyst thinks revenue growth in 2019 will likely be driven by higher demand for newer drugs including Trulicity, Jardiance, Taltz, Verzenio as well as new migraine drug, Emgality as some older drugs like Cialis face generic competition. In 2018, Lilly made significant pipeline progress with several positive late-stage data readouts, multiple approvals and regulatory submissions.
Lilly also added promising new pipeline assets through business development deals. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line.
(You can read the full research report on Eli Lily here >>>).
U.S. Bancorp’s shares have outperformed the Zacks Major Banks industry over the past six months, losing -3.5% vs -10.5%. The company possesses an impressive earnings surprise history, beating expectations in all the trailing four quarters. Fourth-quarter 2018 results reflected higher revenues, aided by elevated fee income. However, reduced mortgage banking revenues and high expenses were on the downside.
The Zacks analyst thinks U.S. Bancorp's prospects will likely get support from its solid business model, core franchise, lower tax rate, rising interest rate and diverse revenue streams. Also, its organic growth remains solid and will likely benefit from the improving economic scenario.
U.S. Bancorp remains well poised to grow through acquisitions. However, escalating expenses due to its ongoing investments in technology and likely increase in legal expenses remain concerns.
(You can read the full research report on U.S. Bancorp here >>>).
Other noteworthy reports we are featuring today include Prudential and Alexion.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free – See the Stocks It Turned Up for Today >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.